16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc.

Private Capital Advisors Inc. acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 16,062 shares of the biopharmaceutical company’s stock, valued at approximately $986,000.

Other large investors also recently bought and sold shares of the company. AlphaQuest LLC lifted its stake in PTC Therapeutics by 337.7% in the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares in the last quarter. Vise Technologies Inc. purchased a new position in PTC Therapeutics during the second quarter worth approximately $486,000. Prudential Financial Inc. boosted its stake in PTC Therapeutics by 35.5% during the second quarter. Prudential Financial Inc. now owns 84,250 shares of the biopharmaceutical company’s stock worth $4,115,000 after buying an additional 22,060 shares during the last quarter. WCM Investment Management LLC purchased a new stake in PTC Therapeutics in the 3rd quarter valued at $8,919,000. Finally, Hussman Strategic Advisors Inc. increased its stake in shares of PTC Therapeutics by 200.0% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 42,000 shares during the last quarter.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CEO Matthew B. Klein sold 7,371 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $511,252.56. Following the completion of the transaction, the chief executive officer owned 387,082 shares in the company, valued at $26,848,007.52. The trade was a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 3,019 shares of PTC Therapeutics stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $69.48, for a total value of $209,760.12. Following the completion of the transaction, the vice president owned 105,212 shares of the company’s stock, valued at approximately $7,310,129.76. This trade represents a 2.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 167,765 shares of company stock worth $12,617,737 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

PTC Therapeutics Trading Down 1.8%

PTCT stock opened at $67.76 on Thursday. The business’s fifty day moving average price is $74.52 and its 200 day moving average price is $68.44. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50. The company has a market capitalization of $5.61 billion, a PE ratio of 8.75 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The business’s revenue was down 22.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.85) earnings per share. Research analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on PTCT. Wall Street Zen lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research note on Thursday, January 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a research report on Friday, February 20th. Barclays reiterated an “overweight” rating and issued a $120.00 price objective on shares of PTC Therapeutics in a report on Monday. Finally, Bank of America reduced their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.93.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.